Eagle Pharmaceuticals ROA 2013-2018 | EGRX

Current and historical return on assets (ROA) values for Eagle Pharmaceuticals (EGRX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Eagle Pharmaceuticals ROA for the three months ending September 30, 2018 was 12.23%.
Eagle Pharmaceuticals ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $0.03B $0.27B 10.92%
2018-06-30 $0.03B $0.27B 11.32%
2018-03-31 $0.03B $0.25B 12.72%
2017-12-31 $0.05B $0.27B 21.18%
2017-09-30 $0.10B $0.27B 43.20%
2017-06-30 $0.10B $0.22B 48.14%
2017-03-31 $0.11B $0.23B 57.14%
2016-12-31 $0.08B $0.21B 50.70%
2016-09-30 $0.03B $0.15B 18.18%
2016-06-30 $0.00B $0.15B 2.29%
2016-03-31 $-0.02B $0.13B -14.49%
2015-12-31 $0.00B $0.13B 2.41%
2015-09-30 $-0.00B $0.12B -3.78%
2015-06-30 $-0.00B $0.12B -3.39%
2015-03-31 $0.00B $0.13B 2.75%
2014-12-31 $-0.02B $0.05B -37.33%
2014-09-30 $-0.02B $0.05B -43.43%
2014-06-30 $-0.01B $0.06B -28.57%
2014-03-31 $-0.01B $0.06B -34.15%
2013-12-31 $-0.01B $0.00B -222.22%
2013-09-30 $-0.01B $0.02B -88.89%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.627B $0.237B
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $125.560B 25.44
Medtronic (MDT) Ireland $116.845B 17.47
Stryker (SYK) United States $62.070B 23.40
Boston Scientific (BSX) United States $51.560B 26.06
Baxter (BAX) United States $37.069B 23.94
Zimmer Biomet Holdings (ZBH) United States $21.197B 13.75
ResMed (RMD) United States $16.739B 31.92
Smith & Nephew SNATS (SNN) United Kingdom $16.480B 0.00
Canopy Growth (CGC) Canada $10.136B 0.00
Bio-Rad Laboratories (BIO) United States $7.056B 45.12
Hill-Rom Holdings (HRC) United States $6.447B 20.36
Aurora Cannabis (ACB) Canada $6.178B 32.58
Perrigo (PRGO) Ireland $6.105B 9.27
Haemonetics (HAE) United States $5.072B 44.61
ICU Medical (ICUI) United States $4.894B 27.27
Insulet (PODD) United States $4.517B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $4.200B 0.00
Neogen (NEOG) United States $3.138B 48.21
Agios Pharmaceuticals (AGIO) United States $3.041B 0.00
Hutchison China MediTech (HCM) China $2.918B 0.00
National Vision Holdings (EYE) United States $2.467B 47.72
NuVasive (NUVA) United States $2.457B 22.87
Quidel (QDEL) United States $2.042B 26.63
NxStage Medical (NXTM) United States $1.891B 0.00
Aphria (APHA) $1.768B 78.67
Phibro Animal Health (PAHC) United States $1.259B 17.82
AtriCure (ATRC) United States $1.203B 0.00
VAREX IMAGING (VREX) United States $1.038B 20.79
Cardiovascular Systems (CSII) United States $1.001B 1441.00
PetIQ (PETQ) United States $0.788B 20.43
Cerus (CERS) United States $0.764B 0.00
OraSure Technologies (OSUR) United States $0.739B 41.59
Meridian Bioscience (VIVO) United States $0.703B 22.42
Omeros (OMER) United States $0.651B 0.00
Surmodics (SRDX) United States $0.645B 97.61
Lantheus Holdings (LNTH) United States $0.625B 19.36
NanoString Technologies (NSTG) United States $0.623B 0.00
MacroGenics (MGNX) United States $0.487B 0.00
Owens & Minor (OMI) United States $0.481B 5.44
Quanterix (QTRX) United States $0.449B 0.00
LeMaitre Vascular (LMAT) United States $0.449B 22.04
Evolus (EOLS) United States $0.443B 0.00
TG Therapeutics (TGTX) United States $0.361B 0.00
Utah Medical Products (UTMD) United States $0.314B 20.31
Insys Therapeutics (INSY) United States $0.305B 0.00
Bovie Medical (APYX) United States $0.280B 0.00
Vapotherm (VAPO) United States $0.273B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.268B 0.00
Cytosorbents (CTSO) United States $0.230B 0.00
BioLife Solutions (BLFS) United States $0.229B 310.00
Rockwell Medical (RMTI) United States $0.178B 0.00
Fonar (FONR) United States $0.137B 6.88
Chimerix (CMRX) United States $0.132B 0.00
Surface Oncology (SURF) United States $0.132B 0.00
Chembio Diagnostics (CEMI) United States $0.120B 0.00
United-Guardian (UG) United States $0.086B 18.00
Female Health (VERU) United States $0.085B 0.00
InfuSystems Holdings (INFU) United States $0.069B 0.00
Trinity Biotech (TRIB) Ireland $0.060B 16.73
Oramed Pharmaceuticals (ORMP) United States $0.059B 0.00
CAS Medical Systems (CASM) United States $0.056B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Neurotrope (NTRP) United States $0.031B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.020B 0.00
Senestech (SNES) United States $0.019B 0.00
Akers Biosciences Inc (AKER) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.014B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.009B 0.00